Antibody Development and Production is regarded as the most comprehensive event that delivers industry best practices across the spectrum of upstream and downstream processing. By attending, you will learn how companies are developing the latest molecular assessment approaches to optimize manufacturability and product quality and how they are applying smarter and faster tools for rapid process development. Industry leaders will assess the state of the industry and offer solutions to overcome the current capacity issues as they work towards their goals of lean manufacturing and facility optimization.

Featured presentations will demonstrate how to successfully integrate upstream and downstream processing and the integral role played by analytics as they develop the next generation of commercial processes. We will explore the impact of Quality by Design (QbD) and Design of Experiments (DOE) on process development as companies share results of the mock filings that have recently concluded with feedback from FDA and EMEA. In addition, you will learn the impact of QbD on existing products as companies expand the scope of process monitoring and control.

Back By Popular Demand

Five Strategic Discussion Forums: Hear uncensored insights on the industry's most pressing challenges:

• Enabling Technologies (What Tools Will Take Us to the Next Level?)

• Outsourcing of Upstream Bioprocess Development

• Can the Biopharma Industry Make Better Progress Working Together As a Community Rather Than Individual Companies? What Are the Hurdles?

• Using BioSMB™ or Other Multicolumn Approaches to Enable Facility Fit for High-Titer Processes and Decrease Clinical Manufacturing Scale and Costs

• New Technologies for Antibody Purification

FIVE CONFERENCES, SAME VENUE
IBC will be holding three conferences on 1–2 March 2010:

• Technology Transfer of Biopharmaceuticals

• Outsourcing Manufacturing of Biopharmaceuticals

• Process and Product Validation.

Keynote Presentations

“Life Sciences Navigating the Sea Change” by G. Steven Burrill, chief executive officer of Burrill and Company

“Industrialization of MAb Production: Implications, Challenges, and Opportunities” by Dana Andersen, PhD, senior director of process R&D Oceanside operations and engineering at Genentech, Inc.

Featured Presentations

“Battling the Biological and Biochemical Challenges to Efficient Upstream/Downstream Process Integration” by Robert D. Kiss, PhD, director of late-stage cell culture in process R&D at Genentech, Inc.

“Improving Bulk Process Transfer at Centocor: The ‘Process-Fit-to-Plant’ Program” by Charles F. Goochee, PhD, fellow in CMC strategy (large-molecule portfolio management and technical integration) at J&J/Centocor

“Upstream and Downstream Process Development Using a QbD Approach: Results from the CMC Biotech Working Group” by Victor A. Vinci, PhD (director of bioprocess operations and bioproduct R&D at Eli Lilly and Company) and Amit Banerjee, PhD (research fellow in global biologics at Pfizer Inc.)

Past Attendees Say. . .

“The quality of the presenters and the data were exceptional, and few other events give attendees the opportunity to hear from so many well-known figures in the bioprocessing industry.”

“The break-out discussion groups were engaging and interactive.”

“This conference had an atmosphere of open interaction from the questions being asked in the very first session.”

Register Now

IBC has designed conferences packages to fit all your needs. You can register for the best value Five-Day All Access Pass or for the individual conference of your choice. Early registration is encouraged to take advantage of preregistration discounts. Group discounts are also available to groups of three or more. When registering, please mention priority code ADP2010FE.